A primer to gene therapy: Progress, prospects, and problems.

Journal of Inherited Metabolic Disease
Hidde A ZittersteijnRob C Hoeben

Abstract

Genetic therapies based on gene addition have witnessed a variety of clinical successes and the first therapeutic products have been approved for clinical use. Moreover, innovative gene editing techniques are starting to offer new opportunities in which the mutations that underlie genetic diseases can be directly corrected in afflicted somatic cells. The toolboxes underpinning these DNA modifying technologies are expanding with great pace. Concerning the ongoing efforts for their implementation, viral vector-based gene delivery systems have acquired center-stage, providing new hopes for patients with inherited and acquired disorders. Specifically, the application of genetic therapies using viral vectors for the treatment of inborn metabolic disorders is growing and clinical applications are starting to appear. While the field has matured from the technology perspective and has yielded efficacious products, it is the perception of many stakeholders that from the regulatory side further developments are urgently needed. In this review, we summarize the features of state-of-the-art viral vector systems and the corresponding gene-centered therapies they seek to deliver. Moreover, a brief summary is also given on emerging gene editi...Continue Reading

References

Jan 1, 1989·Annual Review of Genetics·J Flint, T Shenk
Mar 3, 1972·Science·T Friedmann, R Roblin
Aug 1, 1983·Proceedings of the National Academy of Sciences of the United States of America·A D MillerI M Verma
Feb 6, 1996·Proceedings of the National Academy of Sciences of the United States of America·Y G KimS Chandrasegaran
Oct 27, 1999·Proceedings of the National Academy of Sciences of the United States of America·N MorralA L Beaudet
Apr 28, 2000·Science·M Cavazzana-CalvoA Fischer
Mar 29, 2001·Molecular Therapy : the Journal of the American Society of Gene Therapy·Z Y ChenM A Kay
Jun 16, 2001·Molecular Therapy : the Journal of the American Society of Gene Therapy·T Friedmann, J O Koss
Jan 19, 2002·Nature Genetics·Daniel G MillerDavid W Russell
Aug 31, 2002·Cell·Astrid R W SchröderFrederic Bushman
Dec 10, 2002·Trends in Molecular Medicine·Asad Mian, Brendan Lee
May 2, 2003·Molecular and Cellular Biology·Matthew H PorteusDavid Baltimore
Jun 5, 2003·Nature Genetics·Hiroyuki NakaiMark A Kay
Jun 23, 2004·Nature Genetics·Daniel G MillerDavid W Russell
Apr 16, 2005·BioEssays : News and Reviews in Molecular, Cellular and Developmental Biology·Manuel A F V Gonçalves
Jun 25, 2005·Current Gene Therapy·Marie-Claude Geoffroy, Anna Salvetti
May 20, 2006·Reviews in Medical Virology·Manuel A F V Gonçalves, Antoine A F de Vries
Jul 11, 2006·The Journal of Clinical Investigation·Qizhen ShiRobert R Montgomery
May 17, 2007·Molecular Therapy : the Journal of the American Society of Gene Therapy·Dwight D KoeberlL Chan
Jul 28, 2007·Science·Anthony DonsanteMark S Sands
Nov 1, 2007·Current Gene Therapy·Lorenz Jager, Anja Ehrhardt
Jan 9, 2008·Molecular Therapy : the Journal of the American Society of Gene Therapy·Susannah I ThornhillAdrian J Thrasher
Dec 23, 2008·Nature Biotechnology·Kevin D FoustBrian K Kaspar
Feb 13, 2009·Molecular Genetics and Metabolism·James M Wilson
Aug 13, 2009·Molecular Therapy : the Journal of the American Society of Gene Therapy·Ute ModlichChristopher Baum
Nov 26, 2009·Science·Matthew J Moscou, Adam J Bogdanove
Jul 28, 2010·The New England Journal of Medicine·Salima Hacein-Bey-AbinaMarina Cavazzana-Calvo

❮ Previous
Next ❯

Methods Mentioned

BETA
genetic modification
transgenic
transfection
transfections
gene knockouts
gene
chemical modifications

Related Concepts

Related Feeds

CRISPR Ribonucleases Deactivation

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on mechanisms that underlie deactivation of CRISPR ribonucleases. Here is the latest research.

CRISPR Genome Editing & Therapy

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of this system for gene editing and therapy in human diseases.

CRISPR (general)

Clustered regularly interspaced short palindromic repeats (CRISPR) are DNA sequences in the genome that are recognized and cleaved by CRISPR-associated proteins (Cas). CRISPR-Cas system enables the editing of genes to create or correct mutations. Discover the latest research on CRISPR here.

CRISPR for Genome Editing

Genome editing technologies enable the editing of genes to create or correct mutations. Clustered regularly interspaced short palindromic repeats (CRISPR) are DNA sequences in the genome that are recognized and cleaved by CRISPR-associated proteins (Cas). Here is the latest research on the use of CRISPR-Cas system in gene editing.

Related Papers

Molecular Therapy : the Journal of the American Society of Gene Therapy
Gregory A Newby, David R Liu
Drug Discovery Today. Technologies
Carlos G Moscoso, Clifford J Steer
© 2022 Meta ULC. All rights reserved